Pfizer under pressure to do new deals as sales fall

Pfizer’s revenue shortfall in the last quarter is reigniting pressure on the New York drugmaker to make deals to return to growth.

Sales declined 2% to $12.9bn (€10.9bn) in the second quarter, Pfizer reported yesterday.

Revenue, which missed the $13.1bn average of estimates, has now fallen for three quarters in a row.